Key result
Chemotherapy-induced cardiotoxicity in breast cancer patients is multifactorial, with interindividual variability determined by the interaction between genetic and phenotypic factors.
Why the study?
What are the cellular mechanisms and genetic susceptibilities associated with chemotherapy-induced cardiotoxicity in patients with breast cancer?
What are the cellular mechanisms and genetic susceptibilities associated with chemotherapy-induced cardiotoxicity in patients with breast cancer?
This review highlights the multifactorial nature of chemotherapy-induced cardiotoxicity in breast cancer and emphasizes the potential future role of pharmacogenomics in predicting and managing this risk.
May guide genetic-informed risk stratification; leaves open prospective validation of predictive models.
No takes yet. Share an insight, caveat, or question.
Mihalcea et al. (2016) conducted a review in Breast cancer and chemotherapy-induced cardiotoxicity. Chemotherapy (Anthracyclines, taxanes, and trastuzumab) was evaluated. Chemotherapy-induced cardiotoxicity in breast cancer patients is multifactorial, with interindividual variability determined by the interaction between genetic and phenotypic factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: